These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32107819)

  • 1. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
    Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
    Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
    Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
    Morfini M; Marchesini E; Paladino E; Santoro C; Zanon E; Iorio A
    Haemophilia; 2015 Mar; 21(2):204-209. PubMed ID: 25274155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
    Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
    Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
    Schep SJ; Fischer K; Boes M; Schutgens REG
    Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of extended half-life recombinant FVIII molecules:
    Lancellotti S; Sacco M; Tardugno M; Mancuso ME; De Cristofaro R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100070. PubMed ID: 36908765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining extended half-life rFVIII-A critical review of the evidence.
    Mahlangu J; Young G; Hermans C; Blanchette V; Berntorp E; Santagostino E
    Haemophilia; 2018 May; 24(3):348-358. PubMed ID: 29633467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
    Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.